TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
BCAL Diagnostics Limited ( (AU:BDX) ) has issued an announcement.
BCAL Diagnostics Limited has entered into a strategic partnership with ClearNote Health, granting BCAL exclusive distribution rights for ClearNote’s Avantect Pancreatic and Avantect Ovarian tests in Australia and New Zealand. This agreement, initially set for two years with potential extensions, positions BCAL to enhance its market presence in the early detection cancer test industry, potentially impacting its operations and stakeholder interests positively.
More about BCAL Diagnostics Limited
Average Trading Volume: 187,991
Technical Sentiment Signal: Hold
Current Market Cap: A$25.25M
See more data about BDX stock on TipRanks’ Stock Analysis page.